Company news
Anges. Inc. (TSE:4563) news
Anges. Inc. news releases on 6ix. Latest, Aug 14, 2026: AnGes : Consolidated Financial Report for the Second Quarter 2026
Press releases & updates
AnGes : Consolidated Financial Report for the Second Quarter 2026
August 14, 2026
AnGes : Notice Regarding the Conduct of a Type B CMC Meeting for the HGF gene therapy product
May 14, 2026
AnGes : Financial Results Summary of 1st Quarter 2026
May 8, 2026
AnGes : Consolidated Financial Report for the First Quarter 2026
May 8, 2026
AnGes : COLLATEGENE® (HGF gene therapy product); Proprietary ＆ USAN Names
April 29, 2026
AnGes : Announcement of Publication of a Paper on Secondary Screening for Mucopolysaccharidoses Using Dried Blood Spots
April 2, 2026
AnGes : Notice of First Patient Dosed in an Investigator-Initiated Clinical Trial Aimed at Preventing Brain Injury in Hemodialysis Patients Using the Jointly Developed Tie2 Receptor Agonist (AV-001)
March 24, 2026
AnGes : Notice Regarding the Publication of the Research Article on Our HGF Gene Therapy Product in Circulation
March 10, 2026
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients
March 4, 2026
AnGes : NOTICE OF THE 27TH ANNUAL GENERAL MEETING OF SHAREHOLDERS
March 2, 2026
AnGes : Notice Regarding Partial Changes to the Use of Proceeds from the Issuance of the 46th Stock Acquisition Rights
February 24, 2026
AnGes : Notice Regarding Execution of an Unsecured Private Placement Bond Facility (Revolving Type) Total Amount Purchase Agreement and Issuance of the 2nd Unsecured Corporate Bonds (Private Placement)
February 24, 2026
AnGes : Introduction of the Policy Regarding Actions to Address Large-Scale Purchases of the Company’s Shares, etc. (Takeover Response Policy)
February 16, 2026
AnGes : Consolidated Financial Report for the Fiscal Year 2025
February 10, 2026
AnGes : Notice Regarding the Type “B” Clinical Meeting for HGF Gene Therapy Product
January 6, 2026
AnGes : Notice of Joint Research Agreement on Zokinvy
December 9, 2025
Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications
November 25, 2025
AnGes : Consolidated Financial Report for the Third Quarter 2025
November 7, 2025
AnGes : Notice Regarding Revision of Consolidated Earnings Forecast for the Fiscal Year Ending December 2025
October 27, 2025
AnGes : Notice of Expansion of License Agreement Scope by Our Subsidiary
September 4, 2025
AnGes : Notice Regarding the Initiation of a New Clinical Study for the Jointly Developed Tie2 Receptor Agonist (AV-001)
September 3, 2025
AnGes : ACRL Announcement on Commencement of Biomarker Testing for Mucopolysaccharidosis
August 26, 2025
HGF Gene Therapy Product: AnGes and Boehringer Enter Manufacturing Collaboration
August 20, 2025
AnGes : Consolidated Financial Report for the Second Quarter 2025
August 8, 2025